Clinical trials: Agitation
Delirium in the Intensive Care Unit, Sleep Quality in Adult ICU Patients
Virtual Reality to Reduce Anxiety, Agitation and Delirium in Critically Ill Patients
This is a pilot feasibility study examining the use of immersive virtual reality (VR) in adult intensive care unit (ICU) patients.
- Conditions
- Delirium in the Intensive Care Unit, Sleep Quality in Adult ICU Patients, Agitation Associated With Critical Illness, Anxiety Acute
- Trial name
- NCT07649876
- Testing
- Virtual reality (VR) therapy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Dexmedetomidine, Emergence Agitation
Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal…
- Trial name
- NCT07523438
- Testing
- high dex group, low dex group
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Alexandria University
Agitation in Dementia, Including Alzheimer's Disease
Virtual Darkness Theraphy for Agitation in Dementia
Behavioral and psychological symptoms of dementia (BPSD) such as anxiety, depression, psychosis and agitation, are prevalent, often treatment resistant, resource demanding and significantly deteriorates cognition, independency…
- Trial name
- DARKDEM (NCT06451952)
- Testing
- Virtual darkness
- Where
- Norway
- Volunteers
- 72 people
- Sponsor
- University of Bergen
Delirium, Critical Illness
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
Ventilated pediatric patients are frequently over-sedated and the majority suffer from delirium, a form of acute brain dysfunction that is an independent predictor of increased risk of dying, length of stay, and costs.
- Conditions
- Delirium, Critical Illness, Sedation Complication, Executive Dysfunction
- Trial name
- mini-MENDS (NCT04801589)
- Testing
- Dexmedetomidine, Midazolam
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Vanderbilt University Medical Center
Emergence Agitation, Vocal Cord Polyps
Intranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy
This is a single-center, prospective, single-blinded, randomized controlled trial conducted at The First Hospital of Jilin University.
- Trial name
- NCT07880938
- Testing
- Dexmedetomidin, Esketamine
- Where
- China
- Volunteers
- 134 people
- Sponsor
- The First Hospital of Jilin University
Alzheimer Disease, Agitation
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in…
- Trial name
- NCT06937229
- Testing
- KarXT, KarX-EC
- Where
- 252 sites in United States, Argentina and 24 more
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Emergence Agitation, Emergence Delirium
Effect of Nebulized Lignocaine on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Patients Undergoing Tonsillectomy
Emergence agitation is a frequent recovery complication in young children following general anesthesia with sevoflurane. It is characterized by confusion, crying, disorientation, and non-purposeful thrashing during early…
- Conditions
- Emergence Agitation, Emergence Delirium, Postoperative Pain
- Trial name
- NCT07871266
- Testing
- Lidocaine, 0.9% Normal Saline
- Volunteers
- 60 people
- Sponsor
- Assiut University
Agitation
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
- Trial name
- NCT06052254
- Testing
- 12 cm2 - 2 Active DMTS Patches
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Teikoku Pharma USA, Inc.
Alzheimer's Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Trial name
- NCT07011745
- Testing
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule
- Where
- 143 sites in United States, Argentina and 12 more
- Volunteers
- 426 people
- Sponsor
- Bristol-Myers Squibb
Agitation, Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
- Trial name
- NCT06808984
- Testing
- BMS-986368
- Where
- 77 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Celgene
Emergence Agitation
Preemptive Intravenous Micro-dose Dexmedetomidine to Prevent Emergence Agitation in Adult Patients Undergoing Septoplasty Surgeries
This prospective randomized controlled study will be conducted to evaluate the effect of preoperative single, micro-dose of dexmedetomidine (0.3μg/kg) on the incidence and severity of EA in adults undergoing Septoplasty surgeries
- Trial name
- NCT07302815
- Testing
- Dexmedetomidine, Saline
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Tanta University
Emergence Delirium, Emergence Agitation
Remifentanil vs Fentanyl in Children 7-12 After Urologic Surgery: Emergence Delirium and Recovery Quality
Emergence delirium (agitation) is a common complication in children recovering from general anesthesia, especially after sevoflurane.
- Conditions
- Emergence Delirium, Emergence Agitation, Anesthesia Recovery Period, Postoperative Complications
- Trial name
- NCT07800845
- Testing
- Opioids
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people
- Sponsor
- Konya City Hospital
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
- Trial name
- NCT05665088
- Testing
- BXCL501
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- BioXcel Therapeutics Inc
Dementia
Decoding Death and Dying in People With Dementia by Digital Thanotyping
How can healthcare professionals recognize that a person with dementia is at the end of life? When people are dying, their physical, mental, and social abilities are gradually declining.
- Trial name
- 5-D (NCT06437132)
- Testing
- No intervention
- Where
- Norway
- Volunteers
- 270 people
- Sponsor
- University of Bergen
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Nasal Disease, Agitation, Emergence
Dexmedetomidine and Agitation After Nasal Surgery
The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal…
- Trial name
- NCT06867302
- Testing
- Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML), Dexmedetomidine Injection [Precedex]
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fayoum University Hospital
Agitation Associated With Alzheimer's Dementia
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
- Trial name
- NCT06651567
- Testing
- ITI-1284
- Where
- 70 sites in United States, Bulgaria and 6 more
- Volunteers
- 320 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Delirium, Sedation
Neurosteer Bedside Monitoring System
The purpose of this study is to evaluate the clinical utility of Neurosteer's brain monitoring platform for monitoring delirium, sedation, and agitation in intubated and sedated ICU patients.
- Conditions
- Delirium, Sedation, Agitation
- Trial name
- NCT06718764
- Testing
- Neurosteer's single-channel EEG monitoring device
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Agitation Associated With Alzheimer's Disease Dementia
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
- Trial name
- NCT06803823
- Testing
- ONO-2020
- Where
- 39 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.